300759.SZPharmaron Beijing Co., Ltd.
Oct 28, 2026 — Q3 2026 Earnings Release
Chart by TradingViewThe schedule
- Wed28Oct
Quarterly assessment of fundamental operating cash flows and new client conversions into the late year.
- Wed18Nov
Evaluation of legislative risk and executive trade actions impacting Chinese CRO/CDMO operators' access to western clients.
- Tue12Jan
Management's strategic update on non-US capacity scaling and European market penetration to offset potential geopolitical headwinds.
- Mon29Mar
Full-year financial wrap-up detailing the durability of Pharmaron's ~9.7% net income growth amidst a shifting macro landscape.
Past
- Fri28Aug
Actual outcome: Bear · $41.19 at outcome
Price reached or fell below bear floor ($41.50) at outcome date.
Market reaction to Pharmaron's Q2/1H 2026 interim financials, focusing on revenue trajectory and margins against a high valuation baseline.